At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 2, 2026 at 07:30 ET
CorMedix issued a business update ahead of its Q3 2026 earnings call, reaffirming full-year 2026 revenue guidance of $325M-$345M and reporting $355M cash on hand. The CMS 2027 ESRD final rule set a Q1 2027 DefenCath add-on of $8.32 per session, within the company's previously guided 3x-5x range above the current $2.37 rate, and management provided qualitative commentary on the expected quarterly trajectory of the add-on for 2027.
- Cash and cash equivalents as of September 30, 2026: approximately $355 million.
- Full-year 2026 total revenue guidance reaffirmed at $325M-$345M.
- CMS 2027 ESRD final rule provides a Q1 2027 DefenCath post-TDAPA add-on of $8.32 per dialysis session.
- Q1 2027 add-on of $8.32 is within the company's previously guided range of 3x-5x higher than the current $2.37 rate.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access